Skip to main content

Advertisement

SpringerLink
Log in

Modulating Polo-Like Kinase 1 as a Means for Cancer Chemoprevention

  • Expert Review
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Naturally occurring agents have always been appreciated for their medicinal value for both their chemopreventive and therapeutic effects against cancer. In fact, the majority of the drugs we use today, including the anti-cancer agents, were originally derived from natural compounds, either in their native form or modified to enhance their bioavailability or specificity. It is believed that for maximum effectiveness, it will useful to design novel target-based agents for chemoprevention as well as the treatment of cancer. Recent studies have shown that the serine/threonine kinase polo-like kinase (Plk) 1 is widely overexpressed in a variety of cancers and is being increasingly appreciated as a target for cancer management. Additionally, several chemopreventive agents have been shown to inhibit Plk1 in cancer cells. In this review, we will discuss if Plk1 could also be a target for designing novel strategies for cancer chemoprevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

REFERENCES

  1. Vuorelaa P, Leinonenb M, Saikkuc P, Tammelaa P, Rauhad JP, Wennberge T, et al. Natural products in the process of finding new drug candidates. Curr Med Chem. 2004;11:1375–89.

    PubMed  CAS  Google Scholar 

  2. Cheung CH, Coumar MS, Hsieh HP, Chang JY. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs. 2009;18:379–98.

    Article  PubMed  CAS  Google Scholar 

  3. Coumar MS, Cheung CH, Chang JY, Hsieh HP. Advances in Aurora kinase inhibitor patents. Expert Opin Ther Pat. 2009;19:321–56.

    Article  PubMed  CAS  Google Scholar 

  4. Johansson M, Persson JL. Cancer therapy: targeting cell cycle regulators. Anticancer Agents Med Chem. 2008;8:723–31.

    PubMed  CAS  Google Scholar 

  5. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8:547–66.

    Article  PubMed  CAS  Google Scholar 

  6. Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol. 2009;10:265–75.

    Article  PubMed  CAS  Google Scholar 

  7. Berg T. Small-molecule inhibitors of protein–protein interactions. Curr Opin Drug Discov Devel. 2008;11:666–74.

    PubMed  CAS  Google Scholar 

  8. McInnes C, Mezna M, Fischer PM. Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem. 2005;5:181–97.

    Article  PubMed  CAS  Google Scholar 

  9. Schmit TL, Ahmad N. Regulation of mitosis via mitotic kinases: new opportunities for cancer management. Mol Cancer Ther. 2007;6:1920–31.

    Article  PubMed  CAS  Google Scholar 

  10. Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009;14:559–70.

    Article  PubMed  CAS  Google Scholar 

  11. Sunkel CE, Glover DM. polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J Cell Sci. 1988;89(Pt 1):25–38.

    PubMed  Google Scholar 

  12. Llamazares S, Moreira A, Tavares A, Girdham C, Spruce BA, Gonzalez C, et al. polo encodes a protein kinase homolog required for mitosis in Drosophila. Genes Dev. 1991;5:2153–65.

    Article  PubMed  CAS  Google Scholar 

  13. Lee KS, Yuan YL, Kuriyama R, Erikson RL. Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol Cell Biol. 1995;15:7143–51.

    PubMed  CAS  Google Scholar 

  14. Seki A, Coppinger JA, Jang CY, Yates JR, Fang G. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science. 2008;320:1655–8.

    Article  PubMed  CAS  Google Scholar 

  15. Macurek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature. 2008;455:119–23.

    Article  PubMed  CAS  Google Scholar 

  16. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature. 2001;410:215–20.

    Article  PubMed  CAS  Google Scholar 

  17. Mueller PR, Coleman TR, Kumagai A, Dunphy WG. Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science. 1995;270:86–90.

    Article  PubMed  CAS  Google Scholar 

  18. Parker LL, Therton-Fessler S, Piwnica-Worms H. p107wee1 is a dual-specificity kinase that phosphorylates p34cdc2 on tyrosine 15. Proc Natl Acad Sci U S A. 1992;89:2917–21.

    Article  PubMed  CAS  Google Scholar 

  19. Roshak AK, Capper EA, Imburgia C, Fornwald J, Scott G, Marshall LA. The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal. 2000;12:405–11.

    Article  PubMed  CAS  Google Scholar 

  20. van Leuken R, Clijsters L, van Zon W, Lim D, Yao X, Wolthuis RM, et al. Polo-like kinase-1 controls Aurora A destruction by activating APC/C-Cdh1. PLoS One. 2009;4:e5282.

    Article  PubMed  CAS  Google Scholar 

  21. Chan EH, Santamaria A, Sillje HH, Nigg EA. Plk1 regulates mitotic Aurora A function through betaTrCP-dependent degradation of hBora. Chromosoma. 2008;117:457–69.

    Article  PubMed  CAS  Google Scholar 

  22. De LM, Lavia P, Guarguaglini G. A functional interplay between Aurora-A, Plk1 and TPX2 at spindle poles: Plk1 controls centrosomal localization of Aurora-A and TPX2 spindle association. Cell Cycle. 2006;5:296–303.

    Google Scholar 

  23. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005;5:773–85.

    Article  PubMed  CAS  Google Scholar 

  24. Peters JM. The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol Cell. 2002;9:931–43.

    Article  PubMed  CAS  Google Scholar 

  25. Reimann JD, Freed E, Hsu JY, Kramer ER, Peters JM, Jackson PK. Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. Cell. 2001;105:645–55.

    Article  PubMed  CAS  Google Scholar 

  26. Moshe Y, Boulaire J, Pagano M, Hershko A. Role of polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl Acad Sci U S A. 2004;101:7937–42.

    Article  PubMed  CAS  Google Scholar 

  27. Hansen DV, Loktev AV, Ban KH, Jackson PK. Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1. Mol Biol Cell. 2004;15:5623–34.

    Article  PubMed  CAS  Google Scholar 

  28. Eckerdt F, Strebhardt K. Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res. 2006;66:6895–8.

    Article  PubMed  CAS  Google Scholar 

  29. Burkard ME, Maciejowski J, Rodriguez-Bravo V, Repka M, Lowery DM, Clauser KR, et al. Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol. 2009;7:e1000111.

    Article  PubMed  CAS  Google Scholar 

  30. Randall CL, Burkard ME, Jallepalli PV. Polo kinase and cytokinesis initiation in mammalian cells: harnessing the awesome power of chemical genetics. Cell Cycle. 2007;6:1713–7.

    PubMed  CAS  Google Scholar 

  31. Burkard ME, Randall CL, Larochelle S, Zhang C, Shokat KM, Fisher RP, et al. Chemical genetics reveals the requirement for polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci U S A. 2007;104:4383–8.

    Article  PubMed  CAS  Google Scholar 

  32. Simizu S, Osada H. Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nat Cell Biol. 2000;2:852–4.

    Article  PubMed  CAS  Google Scholar 

  33. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun. 1997;234:397–405.

    Article  PubMed  CAS  Google Scholar 

  34. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene. 2005;24:287–91.

    Article  PubMed  CAS  Google Scholar 

  35. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006;6:321–30.

    Article  PubMed  CAS  Google Scholar 

  36. Schmit TL, Zhong W, Setaluri V, Spiegelman VS, Ahmad N. Targeted depletion of polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol. 2009;129:2843–53.

    Article  PubMed  CAS  Google Scholar 

  37. Schmit TL, Zhong W, Nihal M, Ahmad N. Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle. 2009;8:2697–702.

    PubMed  CAS  Google Scholar 

  38. Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Kobel M, et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer. 2004;90:815–21.

    Article  PubMed  CAS  Google Scholar 

  39. Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate. 2004;60:240–5.

    Article  PubMed  CAS  Google Scholar 

  40. Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A, et al. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch. 2005;446:442–50.

    Article  PubMed  CAS  Google Scholar 

  41. Weichert W, Schmidt M, Jacob J, Gekeler V, Langrehr J, Neuhaus P, et al. Overexpression of polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology. 2005;5:259–65.

    Article  PubMed  CAS  Google Scholar 

  42. Weichert W, Kristiansen G, Schmidt M, Gekeler V, Noske A, Niesporek S, et al. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol. 2005;11:5644–50.

    PubMed  CAS  Google Scholar 

  43. Weichert W, Ullrich A, Schmidt M, Gekeler V, Noske A, Niesporek S, et al. Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Sci. 2006;97:271–6.

    Article  PubMed  CAS  Google Scholar 

  44. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol. 2002;29:354–8.

    Article  PubMed  Google Scholar 

  45. Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R. Prognostic value of pololike kinase expression in melanomas. JAMA. 2000;283:479–80.

    Article  PubMed  CAS  Google Scholar 

  46. Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y, et al. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene. 2004;23:5901–11.

    Article  PubMed  CAS  Google Scholar 

  47. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest. 2005;115:978–85.

    PubMed  CAS  Google Scholar 

  48. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res. 2009;69:6969–77.

    Article  PubMed  CAS  Google Scholar 

  49. Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K, et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia. 2009;23:1564–76.

    Article  PubMed  CAS  Google Scholar 

  50. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, et al. BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res. 2009;15:3094–102.

    Article  PubMed  CAS  Google Scholar 

  51. Emmitte KA, Andrews CW, Badiang JG, vis-Ward RG, Dickson HD, Drewry DH, et al. Discovery of thiophene inhibitors of polo-like kinase. Bioorg Med Chem Lett. 2009;19:1018–21.

    Article  PubMed  CAS  Google Scholar 

  52. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2008;26:5511–7.

    Article  PubMed  CAS  Google Scholar 

  53. Santamaria A, Neef R, Eberspacher U, Eis K, Husemann M, Mumberg D, et al. Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell. 2007;18:4024–36.

    Article  PubMed  CAS  Google Scholar 

  54. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol. 2007;17:316–22.

    Article  PubMed  CAS  Google Scholar 

  55. Stevenson CS, Capper EA, Roshak AK, Marquez B, Eichman C, Jackson JR, et al. The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J Pharmacol Exp Ther. 2002;303:858–66.

    Article  PubMed  CAS  Google Scholar 

  56. Garcia-Pichel F, Sherry ND, Castenholz RW. Evidence for an ultraviolet sunscreen role of the extracellular pigment scytonemin in the terrestrial cyanobacterium Chlorogloeopsis sp. Photochem Photobiol. 1992;56:17–23.

    Article  PubMed  CAS  Google Scholar 

  57. Sorrels CM, Proteau PJ, Gerwick WH. Organization, evolution, and expression analysis of the biosynthetic gene cluster for scytonemin, a cyanobacterial UV-absorbing pigment. Appl Environ Microbiol. 2009;75:4861–9.

    Article  PubMed  CAS  Google Scholar 

  58. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD, et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol. 1996;16:1722–33.

    PubMed  CAS  Google Scholar 

  59. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence Jr JC, Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996;15:5256–67.

    PubMed  CAS  Google Scholar 

  60. Liu Y, Shreder KR, Gai W, Corral S, Ferris DK, Rosenblum JS. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem Biol. 2005;12:99–107.

    Article  PubMed  CAS  Google Scholar 

  61. Liu Y, Jiang N, Wu J, Dai W, Rosenblum JS. Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J Biol Chem. 2007;282:2505–11.

    Article  PubMed  CAS  Google Scholar 

  62. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell. 2000;6:909–19.

    Article  PubMed  CAS  Google Scholar 

  63. Kang GY, Lee ER, Kim JH, Jung JW, Lim J, Kim SK, et al. Downregulation of PLK-1 expression in kaempferol-induced apoptosis of MCF-7 cells. Eur J Pharmacol. 2009;611:17–21.

    Article  PubMed  CAS  Google Scholar 

  64. Reindl W, Yuan J, Kramer A, Strebhardt K, Berg T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein–protein interactions. Chem Biol. 2008;15:459–66.

    Article  PubMed  CAS  Google Scholar 

  65. Gali-Muhtasib H, Roessner A, Schneider-Stock R. Thymoquinone: a promising anti-cancer drug from natural sources. Int J Biochem Cell Biol. 2006;38:1249–53.

    Article  PubMed  CAS  Google Scholar 

  66. Elia AE, Cantley LC, Yaffe MB. Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science. 2003;299:1228–31.

    Article  PubMed  CAS  Google Scholar 

  67. Watanabe N, Sekine T, Takagi M, Iwasaki J, Imamoto N, Kawasaki H, et al. Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem. 2009;284:2344–53.

    Article  PubMed  CAS  Google Scholar 

  68. Kulling SE, Lehmann L, Metzler M. Oxidative metabolism and genotoxic potential of major isoflavone phytoestrogens. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;777:211–8.

    Article  PubMed  CAS  Google Scholar 

  69. Taylor CK, Levy RM, Elliott JC, Burnett BP. The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr Rev. 2009;67:398–415.

    Article  PubMed  Google Scholar 

  70. Ismail IA, Kang KS, Lee HA, Kim JW, Sohn YK. Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation. Eur J Pharmacol. 2007;575:12–20.

    Article  PubMed  CAS  Google Scholar 

  71. Cheng WY, Hsiang CY, Bau DT, Chen JC, Shen WS, Li CC, et al. Microarray analysis of vanillin-regulated gene expression profile in human hepatocarcinoma cells. Pharmacol Res. 2007;56:474–82.

    Article  PubMed  CAS  Google Scholar 

  72. Ho K, Yazan LS, Ismail N, Ismail M. Apoptosis and cell cycle arrest of human colorectal cancer cell line HT-29 induced by vanillin. Cancer Epidemiol. 2009;33:155–60.

    Article  PubMed  CAS  Google Scholar 

  73. Kaur M, Agarwal R. Silymarin and epithelial cancer chemoprevention: how close we are to bedside? Toxicol Appl Pharmacol. 2007;224:350–9.

    Article  PubMed  CAS  Google Scholar 

  74. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev. 2009;18:13–25.

    Article  PubMed  CAS  Google Scholar 

  75. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008;269:352–62.

    Article  PubMed  CAS  Google Scholar 

  76. Cui W, Gu F, Hu KQ. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol. 2009;15:1943–50.

    Article  PubMed  CAS  Google Scholar 

  77. Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA, et al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene. 2003;22:8271–82.

    Article  PubMed  CAS  Google Scholar 

  78. Noh EJ, Lim DS, Jeong G, Lee JS. An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochem Biophys Res Commun. 2009;378:326–31.

    Article  PubMed  CAS  Google Scholar 

  79. Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K. A new antifungal antibiotic, trichostatin. J Antibiot (Tokyo). 1976;29:1–6.

    CAS  Google Scholar 

  80. Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays. 1995;17:423–30.

    Article  PubMed  CAS  Google Scholar 

  81. Lee JS. Activation of ATM-dependent DNA damage signal pathway by a histone deacetylase inhibitor, trichostatin A. Cancer Res Treat. 2007;39:125–30.

    Article  PubMed  Google Scholar 

  82. Kim SA, Kim SW, Chang S, Yoon JH, Ahn SG. 5′-nitro-indirubinoxime induces G2/M cell cycle arrest and apoptosis in human KB oral carcinoma cells. Cancer Lett. 2009;274:72–7.

    Article  PubMed  CAS  Google Scholar 

  83. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol. 1999;1:60–7.

    Article  PubMed  CAS  Google Scholar 

  84. Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S, et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A. 2005;102:5998–6003.

    Article  PubMed  CAS  Google Scholar 

  85. Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol. 2004;130:627–35.

    Article  PubMed  CAS  Google Scholar 

  86. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 2001;276:251–60.

    Article  PubMed  CAS  Google Scholar 

  87. Kim SA, Kim YC, Kim SW, Lee SH, Min JJ, Ahn SG, et al. Antitumor activity of novel indirubin derivatives in rat tumor model. Clin Cancer Res. 2007;13:253–9.

    Article  PubMed  CAS  Google Scholar 

  88. Kim SH, Choi SJ, Kim YC, Kuh HJ. Anti-tumor activity of noble indirubin derivatives in human solid tumor models in vitro. Arch Pharm Res. 2009;32:915–22.

    Article  PubMed  CAS  Google Scholar 

Download references

ACKNOWLEDGEMENTS

This work was partially supported (Pre-doctoral Traineeship to Travis Schmit) by the Molecular and Environmental Toxicology Center Training Grant (T32ES007015) from the NIEHS, NIH.

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Wisconsin, 1300 University Avenue, Medical Science Center, Room 423, Madison, Wisconsin, 53706, USA

    Travis L. Schmit, Mark C. Ledesma & Nihal Ahmad

  2. Molecular and Environmental Toxicology Center, University of Wisconsin, Madison, Wisconsin, USA

    Travis L. Schmit & Nihal Ahmad

  3. University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, Wisconsin, USA

    Nihal Ahmad

Authors
  1. Travis L. Schmit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark C. Ledesma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nihal Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nihal Ahmad.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmit, T.L., Ledesma, M.C. & Ahmad, N. Modulating Polo-Like Kinase 1 as a Means for Cancer Chemoprevention. Pharm Res 27, 989–998 (2010). https://doi.org/10.1007/s11095-010-0051-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-010-0051-8

KEY WORDS

Search

Navigation